Organization
Novelmed Therapeutics
8 clinical trials
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase II, Open Label, Multi Dose Study of NM8074 in Soliris-Treated Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase II, Open-Label Study of NM8074 in Soliris®-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase II, Open-Label Study of NM8074 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Not yet recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase Ib, Open Label, Dose Escalation Study of NM8074 in Subjects With C3 Glomerulopathy (C3G)Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase II, Open-Label Study of NM8074 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of NM8074 Administered Intravenously to Healthy SubjectsStatus: Completed, Estimated PCD: 2022-06-15
Clinical trial
A Phase II, Open-Label Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)Status: Not yet recruiting, Estimated PCD: 2026-08-01